Hyperinsulinemia may increase the risk of colorectal neoplasia because of its mitogenic and antiapoptotic properties, which have a growth-promoting effect. We examined the association between circulating concentrations of C-peptide, a biomarker of insulin secretion, and colorectal adenoma prevalence in a case-control study of Korean adults. A total of 364 participants (112 cases and 252 controls) were included. Participants who underwent a colonoscopy completed questionnaires and provided blood samples. We used multivariate logistic regression models to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal adenoma. Circulating concentrations of C-peptide were not associated with colorectal adenoma; the multivariate OR (95% CI) was 0.95 (0.51-1.75) comparing the highest tertile with the lowest tertile (p for trend = 0.91). When we used a conditional logistic regression model by fasting status and sex matching, there was still no association (OR = 0.92; 95% CI = 0.43-1.99) when comparing the highest tertile with the lowest tertile. We observed no association between circulating concentrations of C-peptide and colorectal adenoma prevalence in Korean adults.

**Key Words:** C-peptide, Colorectal adenoma, Hyperinsulinemia

---

**Introduction**

Colorectal cancer is the third most common type of cancer in Korea [1]. The incidence rate of colorectal cancer consistently increased by 5.9% annually from 1999 to 2010 [1]. Several epidemiologic studies suggest that obesity, physical inactivity, and the Western dietary pattern—rich in refined grain and sugar, red/processed meat and energy-dense food—are associated with an increased risk of colorectal cancer [2]. The potential hypothesis suggested that these lifestyles may increase colorectal tumorigenesis through alterations in the metabolism of insulin and insulin-like growth factors (IGFs) [3,4]. Insulin is a known key regulator of energy metabolism and may increase the bioactivity of IGF-1 by inhibiting the production of the IGF-binding protein (BP)-1 and perhaps IGFBP-2 [5]. The anabolic signals of insulin and IGF-1 can promote tumor development by inhibiting apoptosis and increasing cell proliferation [6,7].
C-peptide is secreted by beta cells on an equal molar basis with insulin; therefore, it is regarded as a marker of insulin secretion [8]. Because of the possible link between hyperinsulinemia and cancer risk, several epidemiologic studies have explored whether circulating concentrations of C-peptide could be a potential predictor of several cancer risks, including cancers of the breast [9], prostate [10], pancreas [11] and endometrium [12]. A recent meta-analysis of prospective studies suggested evidence of an increased risk of colorectal neoplasia with increased C-peptide [13], but only a few Asian studies examined the association with colorectal cancer [2,14,15]. For colorectal adenoma, the evidence linking hyperinsulinemia is more limited.

Therefore, we examined whether circulating concentrations of C-peptide were related to colorectal adenoma in Korean adults.

Materials and Methods

Study Population and Case Ascertainment

The study participants were 382 men and women aged 45-71 years who underwent colonoscopy from August 2011 to September 2012 and provided blood samples after re-invitation at a university hospital in Daegu, city of Korea. Participants were excluded if they had any type of cancer (n = 14) or had an energy intake beyond the mean energy intake by more than three standard deviations (n = 4). As a result, a total of 364 participants were included.

The sizes, subtypes, and number of colorectal adenomas were determined through a colonoscopy and pathological examination. Polyps were classified as adenomatous, hyperplastic, or other non adenomatous. Only adenomatous polyps were included as cases. We included both first and recurrent adenomas (n = 17; 4.7%). Adenomas were classified to the right colon if participants had at least one adenoma at the cecum, ascending colon, hepatic flexure, or transverse colon. Adenomas were classified to the left colon if participants had at least one adenoma at the splenic flexure, descending colon, sigmoid colon, or rectum [16]. Of 364 participants, a total of 112 cases and 252 controls were included in the analysis. To minimize the influence of fasting status or sex, we performed 1:1 matching by fasting status and sex and examined the association in the additional analysis. Written informed consent was obtained from all participants. This study was approved by the Institutional Review Board of Daegu Catholic University Medical Center.

Measurement of C-peptide

Blood samples were drawn from the participants, centrifuged, and sent on ice to the Neodin medical institute between January and February 2013. Serum concentrations of C-peptide were measured by the electrochemiluminescence immunoassay (ECLIA) method by using a Cobas 6000 at Neodin medical institute (Seoul, South Korea). All laboratory technicians were blinded to the case status. The intra-assay coefficient of variations (CV) was 2.5-3.5%.

Assessment of Lifestyle and Anthropometric Factors

Participants were asked about their demographic characteristics including the type, frequency, and duration of exercise, alcohol and tobacco use, family history of colorectal cancer, menopausal status (in women only), use of hormone replacement therapy (in women only), nutritional supplement use, and dietary intake. Participants' height and weight were measured by using X-scan plus II professional (Jawon medical, Gyeongsan, South Korea). The waist circumference was measured at the midpoint between the lower margin of the rib cage and the upper margin of the iliac crest. The body mass index (BMI) was calculated by dividing the weight in kilograms by the square of height in meters. The metabolic equivalent of task (MET)-hours per week was calculated for physical activity, which was assessed using a list of questionnaire items similar, but modified, with the Minnesota Leisure Time Physical Activity Questionnaire.

Statistical Analysis

For participants’ characteristics, we calculated the means and standard deviations (SD) of continuous variables and the frequencies and percentages of categorical variables. Differences in characteristics were calculated by either the t-test for continuous variables or chi-square test for categorical variables. We used logistic regression models to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal adenoma. We adjusted for age (years, continuous), sex (men, women), waist circumference (cm, continuous), fasting status (<4, 4-8, >8 hours, unknown), alcohol consumption (nondrinker, past drinker, ≤4 drinks per month, ≥2 drinks per week), and pack-years of smoking (never, 1-<20, 20-<30, ≥30). Because additional adjustment for family history of colorectal cancer, red meat consumption, vegetables and fruits consumption, aspirin use and physical activity did not appreciably alter the association between C-peptide and colorectal adenoma, we
C-Peptide and Colorectal Adenoma

C-Peptide and Colorectal Adenoma

did not include these factors in the analysis. We also examined whether associations varied by potential effect modifiers. Heterogeneity by each effect modifier was tested by including a cross-product term of the main exposure and interaction terms using the likelihood ratio test. We used the median of each C-peptide category as a continuous variable to test for linear trends. All p values were two-sided, and a p value < 0.05 was considered statistically significant. All analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

Discussion

Our case-control study found no association between circulating levels of C-peptide and colorectal adenoma prevalence. When we examined the associations among men and women separately, we still found no statistically significant associations. We also found no associations when we stratified into right or left colon. The median values of C-peptide concentration were 4.3 ng/mL among male controls and 3.6 ng/mL among female controls, which were similar to those in the US Hawaiian multiethnic study [17], but higher than those in the Japan Public Health Center-based Prospective study [14].

The current evidence linking hyperinsulinemia to colorectal adenoma has remained inconsistent. A recent meta-analysis of nested case-control studies found an OR of 1.39 (95% CI = 1.04–1.87) for colorectal neoplasia [13] but no association for colorectal adenoma (OR = 1.42; 95% CI = 0.95–2.13) [13]. In this meta-analysis, two studies were included: the Nurses' Health Study, including 380 case-control pairs, found that high concentrations of C-peptide were associated with a risk of distal colorectal adenoma [18], whereas the CLUE II cohort (132 cases, 260 controls) found no association [19]. In the US Hawaiian population study, high plasma levels of C-peptide were statistically significantly associated with a risk of colorectal adenoma [17]. A review of the studies examining C-peptide and colorectal adenoma showed a more pronounced association for men than women [15,20]. However, our study observed no associations among men or women.

Hyperinsulinemia, reflected in high circulating concentrations of C-peptide, may increase cancer risk through promotion of the bioactivity of IGF-1. IGF-1 inhibits apoptosis and promotes proliferation [15]. Additionally, insulin may exert interaction with IGFBPs, which modulates the bioavailability of IGFs. Under low IGFBP levels, IGF mitogenic activity is expected to be high. Insulin decreases IGFBP-1 expression [21] and IGFBP-2 concentrations [22]. Increased bioactivity of IGF-1 partly by inhibiting the production of IGFBP-1 and IGFBP-2 could stimulate tumorigenesis. A direct mitogenic effect by increasing the activity of the Ras protein could be another potential mechanism, given that insulin increases the pool of farnesylated Ras protein [23,24].

The limitations of our study are as follows: the one-time measurement of C-peptide reduced our ability to evaluate associations between long-term circulating concentrations of C-peptide and colorectal adenoma. But C-peptide levels have previously been reported to be relatively stable [25]. We had a
Table 1. Characteristics of patients according to case status*†

|                                | Adenoma (n = 112) | No adenoma (n = 252) | p value‡ |
|--------------------------------|-------------------|----------------------|----------|
| Age, years                     | 60.3 ± 5.3        | 59.2 ± 5.0           | 0.06     |
| Sex                            |                   |                      | <0.0001  |
| Men                            | 57 (50.9)         | 69 (27.4)            |          |
| Women                          | 55 (49.1)         | 183 (72.6)           |          |
| C-peptide, ng/mL               | 4.7 ± 3.1         | 4.2 ± 2.2            | 0.10     |
| Education                      |                   |                      | 0.25     |
| Elementary school graduate     | 16 (14.3)         | 33 (13.2)            |          |
| Middle school graduate         | 25 (22.3)         | 81 (32.4)            |          |
| High school graduate           | 50 (44.6)         | 100 (40.0)           |          |
| College graduate or above      | 21 (18.8)         | 36 (14.4)            |          |
| Waist circumference, cm        | 87.0 ± 7.8        | 84.2 ± 7.4           | <0.001   |
| BMI, kg/m²                     |                   |                      | 0.21     |
| BMI < 23                       | 33 (29.5)         | 73 (29.0)            |          |
| 23 ≤ BMI < 25                  | 32 (28.6)         | 94 (37.3)            |          |
| 25 ≤ BMI                       | 47 (42.0)         | 85 (33.7)            |          |
| Family history of colorectal cancer |             |                      | 0.33     |
| Yes                            | 6 (5.4)           | 8 (3.2)              |          |
| No                             | 106 (94.6)        | 242 (96.8)           |          |
| Hormone replacement therapy (HRT) |               |                      | 0.95     |
| Premenopausal status           | 3 (7.5)           | 11 (7.3)             |          |
| Postmenopausal status without HRT | 24 (60.0) | 94 (62.7)            |          |
| Postmenopausal status with HRT | 13 (32.5)         | 45 (30.0)            |          |
| Smoking status                 |                   |                      | <0.0001  |
| Non smoker                     | 56 (50.9)         | 190 (76.9)           |          |
| Past smoker                    | 37 (33.6)         | 39 (15.8)            |          |
| Current smoker                 | 17 (15.5)         | 18 (7.3)             |          |
| Pack years (in smoker)         | 26.4 ± 13.4       | 25.9 ± 15.5          | 0.87     |
| Alcohol drinking               |                   |                      | 0.01     |
| Never drinker                  | 41 (36.6)         | 137 (54.4)           |          |
| Past drinker                   | 6 (5.4)           | 8 (3.2)              |          |
| Current drinker                | 65 (58.0)         | 107 (42.5)           |          |
| Physical activity (MET-hr/wk)  | 29.0 ± 32.0       | 25.9 ± 24.1          | 0.87     |
| Supplement use                 |                   |                      | 0.01     |
| Yes                            | 42 (37.5)         | 130 (51.6)           |          |
| No                             | 70 (62.5)         | 122 (48.4)           |          |
| Red meat intake                |                   |                      | 0.12     |
| ≤1 serving/month               | 11 (10.1)         | 29 (11.6)            |          |
| 2-4 servings/month             | 77 (70.6)         | 194 (77.3)           |          |
| ≥2 servings/week               | 21 (19.3)         | 28 (11.2)            |          |

BMI: body mass index, HRT: hormone replacement therapy, MET: metabolic equivalent of task.
*Values are presented as mean ± SD or n (column %); †The sum of number of participants for some variables did not match the total sample size because some participants did not provide information on these variables; ‡p values were based on chi-square test for categorical variables and t-test for continuous variables.
C-Peptide and Colorectal Adenoma

Table 2. Odds ratios and 95% confidence intervals for colorectal adenoma prevalence according to serum concentrations of C-peptide

| Circulating concentrations of C-peptide | Tertile 1 | Tertile 2 | Tertile 3 | p for trend |
|----------------------------------------|-----------|-----------|-----------|-------------|
| All patients                            |           |           |           |             |
| Median, ng/mL                           | 2.1       | 3.9       | 6.4       |             |
| No. of case/control                     | 37/84     | 31/91     | 44/77     |             |
| Model 1†                                | 1.00      | 0.73 (0.41-1.31) | 1.14 (0.66-1.99) | 0.52 |
| Model 2‡                                | 1.00      | 0.77 (0.42-1.43) | 0.95 (0.51-1.75) | 0.91 |
| Men                                     |           |           |           |             |
| Median, ng/mL                           | 2.1       | 4.3       | 7.6       |             |
| No. of case/control                     | 18/24     | 22/20     | 17/25     |             |
| Model 1                                 | 1.00      | 1.43 (0.60-3.40) | 0.90 (0.38-2.14) | 0.72 |
| Model 2                                 | 1.00      | 1.90 (0.67-5.40) | 0.55 (0.19-1.58) | 0.22 |
| Women                                   |           |           |           |             |
| Median, ng/mL                           | 2.0       | 3.6       | 5.9       |             |
| No. of case/control                     | 21/58     | 12/68     | 22/57     |             |
| Model 1                                 | 1.00      | 0.48 (0.22-1.07) | 1.06 (0.53-2.14) | 0.68 |
| Model 2                                 | 1.00      | 0.52 (0.23-1.17) | 1.13 (0.53-2.41) | 0.62 |
| Right colon‡                            |           |           |           |             |
| Median, ng/mL                           | 2.1       | 3.8       | 6.4       |             |
| No. of case/control                     | 22/84     | 22/91     | 26/77     |             |
| Model 1                                 | 1.00      | 0.87 (0.44-1.71) | 1.10 (0.56-2.15) | 0.72 |
| Model 2                                 | 1.00      | 0.79 (0.38-1.65) | 0.89 (0.43-1.87) | 0.81 |
| Left colon‡                             |           |           |           |             |
| Median, ng/mL                           | 2.1       | 3.9       | 6.4       |             |
| No. of case/control                     | 19/84     | 16/91     | 25/77     |             |
| Model 1                                 | 1.00      | 0.79 (0.37-1.67) | 1.24 (0.62-2.50) | 0.47 |
| Model 2                                 | 1.00      | 1.06 (0.47-2.38) | 1.05 (0.47-2.32) | 0.92 |

*Adjusted for sex (men, women), and age (continuous); †Adjusted for sex (men, women), age (years, continuous), waist circumference (cm, continuous), fasting status (<4, 4-8, >8 hours, unknown), alcohol drinking (nondrinker, past drinker, ≤4 drinks/month, ≥2 drinks/week), and pack-years of smoking (never, 1-<20, 20-<30, ≥30); ‡A total of 18 cases had both left and right colon adenomas.

Additionally, the results may not be generalizable to the general Korean population. We cannot rule out the possibility that residual or unmeasured confounding factors remained. One of this study’s strengths is that all participants underwent a colonoscopy, which reduces the possibility of misclassification of outcomes. We were able to adjust for known confounding factors.

**Conclusion**

We found no association between circulating concentrations of C-peptide and colorectal adenoma in our study. However, further prospective studies with a large population are needed to elucidate the role of hyperinsulinemia in the colorectal adenoma-carcinoma sequence.
Table 3. Odds ratios and 95% confidence intervals according to C-peptide concentrations by major risk factors

|                | Circulating concentrations of C-peptide | p for heterogeneity |
|----------------|----------------------------------------|---------------------|
|                | <median | ≥median |                             |
| Age, years†   |         |         |                             |
| <60.0          | 1.00    | 0.92    | (0.48-1.75)                 |
| ≥60.0          | 1.03 (0.52-2.03) | 1.14 (0.57-2.27) |
| Sex            |         |         |                             |
| Men            | 1.00    | 0.77    | (0.36-1.64)                 |
| Women          | 0.77 (0.29-2.08) | 0.91 (0.34-2.46) |
| BMI, kg/m²     |         |         |                             |
| <25            | 1.00    | 1.14    | (0.53-2.46)                 |
| ≥25            | 0.84 (0.43-1.64) | 0.55 (0.27-1.11) |
| Abdominal obesity‡ |         |         |                             |
| Yes            | 1.00    | 1.17    | (0.41-3.39)                 |
| No             | 1.30 (0.60-2.82) | 1.29 (0.60-2.81) |
| Alcohol drinking |         |         |                             |
| Never drinker  | 1.00    | 0.89    | (0.43-1.85)                 |
| Ever drinker   | 1.25 (0.62-2.54) | 1.36 (0.67-2.75) |
| Smoking status |         |         |                             |
| Non smoker     | 1.00    | 1.40    | (0.77-2.57)                 |
| Ever smoker    | 4.23 (1.51-11.88) | 1.95 (0.73-5.21) |
| Physical activity, MET-hr/wk† |         |         |                             |
| <20.9          | 1.00    | 1.19    | (0.60-2.35)                 |
| ≥20.9          | 1.29 (0.65-2.54) | 1.11 (0.57-2.15) |
| Red meat intake, servings/wk† |         |         |                             |
| <2             | 1.00    | 1.16    | (0.68-1.97)                 |
| ≥2             | 2.53 (1.03-6.26) | 1.13 (0.42-3.06) |

BMI: body mass index, MET: metabolic equivalent of task.

*Adjusted for sex (men, women), age (years, continuous), waist circumference (cm, continuous), fasting status (<4, 4-8, >8 hours, unknown), alcohol drinking (nondrinker, past drinker, ≤4 drinks/month, ≥2 drinks/week), and pack-years of smoking (never, 1-<20, 20-<30, ≥30); †Variables were categorized by median values; ‡Abdominal obesity was categorized to yes if waist circumferences were ≥90 cm for men and ≥85 cm for women.

**Acknowledgments**

Funding: This research was supported by the National Research Foundation of Korea (NRF) grant, which was funded by the Korean government (no. 2011-0011028).

**Conflict of interest**

We declare that we have no conflict of interest.

**References**

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45:1-14.
2. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101:1286-91.
3. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp 2004;262:247-60.
4. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704.
5. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-II), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
6. Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eysen G, Bruce WR, Giacca A. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in...
C-Peptide and Colorectal Adenoma

vivo. Endocrinology 2006;147:1830-7.

7. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183-223.

8. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984;33:486-94.

9. Aueter P, Koechlin A, Bonioli M, Mullie P, Bolli G, Rosenstock J, Boyle P. Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. Cancer Causes Control 2013;24:873-83.

10. Lai GY, Helzlsouer KJ, Clipp SL, Rifai N, Platz EA. Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Philad) 2010;3:1334-41.

11. Grote VA, Rohmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluij D, Boeving H, Trichopoulos A, Lagiou P, Trichopoulos D, Pali D, Paal V, Tumino R, Vines P, Pancio S, Rodrigues L, Duell EJ, Molina-Montes E, Dorrondo Sor M, Huerta JM, Ardanaz E, Jeurnink SM, Beu- lens JW, Peeters PH, Sund M, Ye W, Lindqvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboil E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R, Diabetes mellitus, and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011;54:3037-46.

12. Cust AE, Allen NE, Rinaldi S, Dossus L, Tjønneland A, Halkjær J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Chang-Claude J, Boeving H, Schulz M, Benetou V, Trichopoulos A, Trichopoulos D, Pali D, Pala V, Tumino R, Vines P, Pancio S, Rodriguez L, Duell EJ, Molina-Montes E, Dorrondo Sor M, Huerta JM, Ardanaz E, Jeurnink SM, Beu- lens JW, Peeters PH, Sund M, Ye W, Lindqvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboil E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R. Diabetes mellitus and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011;54:3037-46.

13. Chen L, Li L, Wang Y, Li P, Luo L, Yang B, Wang H, Chen M. Circulating C-peptide level is a predictive factor for colorectal neoplasia: evidence from the meta-analysis of prospective studies. Cancer Causes Control 2013;24:1837-47.

14. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center-based Prospective Study Group. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 2007;120:2007-12.

15. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. Int J Obes (Lond) 2012;36:440-7.

16. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 2012;21:411-6.

17. Le Marchand L, Wang H, Rinaldi S, Kaaks R, Vogt TM, Yokochi L, Decker R. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multietnic population. Cancer Epidemiol Biomarkers Prev 2010;19:1471-7.

18. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006;15:750-5.

19. Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2010;21:1-10.

20. Vidal AC, Lund PK, Hoye C, Galanko J, Burral L, Holston R, Massa B, Omofoye O, Sandler RS, Keku TO. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer 2012;12:389.

21. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.

22. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-36.

23. Goalstone ML, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2010;21:1-10.

24. Burgering BM, Medema RH, Maassen JA, van de Wetering ML, van der Eb A, McCormick F, Bos JL. Insulin stimulation of gene expression mediated by p21ras activation. EMBO J 1991;10:1103-9.

25. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53.